Syngene International Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Syngene International’s record is a study in contrasts: six years of unqualified audit opinions and operating cash flow that consistently exceeds profit sit alongside an abrupt auditor resignation, accounting estimates that have materially shaped reported earnings, and a standing Key Audit Matter on revenue recognition. The numbers are audited, but the choices behind them demand attention.

Key findings

  1. The statutory auditor resigned, capping three partner changes in four years Major - B S R & Co. LLP resigned as statutory auditor of Syngene International on 7 July 2026 and of material subsidiary Syngene Scientific Solutions on 8 July 2026, stating “None” for any other facts relevant to the resignation. Its second five-year term was scheduled to conclude at the AGM in 2026, and the engagement partner changed three times across the last four completed fiscal years. The Board has proposed S. R. Batliboi & Associates LLP as the replacement for a five-year term.
  2. Accounting estimates and policy choices have materially shaped reported profit across multiple years Major - A useful-life revision for manufacturing assets cut depreciation by ₹20.6 crore in FY2024-25, and an inventory-provisioning change effective 1 January 2024 produced a net reversal of ₹203 crore in Q4 FY2023-24. Exceptional items recur across years: FY2025-26 carries ₹46.2 crore for gratuity and ₹30.4 crore for termination benefits, FY2023-24 includes ₹111 crore of transaction costs for the Unit 3 acquisition, and FY2021-22 includes a ₹30.7 crore reversal of a government SEIS claim.
  3. Operating cash flow is strong, but heavy capitalisation into CWIP and a ROCE of 8.7% raise questions on capital-allocation returns Major - Consolidated CFO exceeded PAT in every one of the last six fiscal years, covering profit 2.89 times in FY26. Yet CWIP stood at ₹1,046 crore as of 31 March 2026, 41% of gross PP&E, and consolidated ROCE fell from 14.41% in FY23 to 8.68% in FY26. The Baltimore biologics facility alone accumulated ₹298.1 crore in CWIP by March 2025 and a further ₹78.5 crore in pre-operating costs during FY26, and was not yet fully capitalised as of the Q4 FY26 earnings call.
  4. Income-tax disputes spanning three decades remain unresolved, with contingent liabilities rising over time Minor - Standalone disputed income-tax dues totalled 104.42 crore as of 31 March 2026, covering AY 2018-19 to AY 2022-23 and pending before the Commissioner of Income Tax (Appeals). Contingent liabilities from disputed taxes have risen from ₹424.5 crore in FY19 to ₹632.1 crore in FY24, with the company continuing to litigate refund adjustments and receiving mixed appellate outcomes, including a partial allowance for AY 2016-17 on 8 January 2026 and a refund of ₹8.62 crore for AY 2014-15 on 6 July 2026.
  5. Revenue recognition is a standing Key Audit Matter, with two customers supplying over 20% of revenue and a biologics destocking cycle depressing FY26 growth Minor - Revenue recognition is flagged as a Key Audit Matter in every year from FY24 through FY26, citing complex contractual arrangements including bill-and-hold and presumed fraud risk. Two customers each exceeding 10% of revenue together supplied ₹13,926 in FY26, and FY26 revenue growth slowed to 2.6% as a large-molecule biologics product entered a destocking cycle that management said would leave “almost no Librela” in the first two quarters of FY27. A ₹27.7 crore foreign-exchange-driven receivable write-off was recorded in the quarter ended 30 September 2025.
  6. Audit opinions are unqualified, but audit-trail exceptions and delayed statutory dues recur Minor - B S R & Co. LLP issued unqualified opinions on the standalone and consolidated financial statements for every year from FY19 through FY26. The auditor reported that the accounting software’s audit-trail feature did not operate throughout the year for privileged-access data changes in FY24, FY25, and FY26, and the CARO report for FY26 noted delays in depositing undisputed Provident Fund dues, a pattern also reported in FY25, FY23, FY22, and FY20.
  7. A subsidiary incorporated in 2022 never commenced operations and is now being liquidated Minor - Syngene Manufacturing Solutions Limited, incorporated on 26 August 2022, was reported as “yet to commence operations” in every annual report through FY26, with total income of ₹0.06 Cr and nil profit or loss in FY26. The Board approved its voluntary liquidation on 18 May 2026; its net worth was ₹93,97,513, or 0.02% of the company’s net worth.
  8. A single minor listing-rules deviation resulted in a closed ₹20,000 fine; no other regulatory actions appear across any year reviewed Clean - Syngene paid a fine of ₹20,000 to both stock exchanges for a deviation in NRC composition during 22-31 July 2025, and the matter is closed. The FY26 corporate governance report states no non-compliance, penalties, or strictures were imposed by stock exchanges, SEBI, or any statutory authority on capital-markets matters during the last three years.

What to watch

Bottom line: This is a disclosed and audited record with genuine cash generation and a clean regulatory history. The risk sits in the governance signals: an auditor resignation after the scheduled conclusion of its term with no stated reason, accounting estimates that have done heavy lifting for reported profit, and a subsidiary that never commenced operations and is now being liquidated. Watch the shareholder votes on the auditor, the pay ceiling, and the new CEO, and track whether the Baltimore facility’s capitalisation timeline sharpens, because the ROCE number already carries the weight of those choices.